BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · 693-705
DOI: 10.1210/clinem/dgae589 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 26.08.2024. Verfasst von Yiyi Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 64, Sweden. Hauptthemen laut MEDLINE: Telomerase, Proto-Oncogene Proteins B-raf, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Stockholm County Council.
Abstract (Originalsprache)
Context
BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma (PTC) have a synergistic effect on prognosis. This effect is believed to arise from MAPK activation triggered by BRAFV600E, leading to the upregulation of ETS transcription factors that bind to the mutant TERT promoter.
Objectives
To explore the role of ETS factors in relation to clinical features, BRAFV600E, and TERT promoter mutations in PTC.
Design
Transcriptomic data for 28 ETS factors were analyzed in the PTC cohort of The Cancer Genome Atlas (n = 399) and subsequently validated in a local cohort (n = 93). In vitro experiments were performed to investigate the regulatory role in relation to BRAFV600E and TERT expression.
Results
The Cancer Genome Atlas identified ETS1, ERG, FLI1, GABPA, EHF, ETV6, and SPDEF as differentially expressed genes between stages I + II and III + IV. In both cohorts, EHF was consistently associated with adverse clinical features, BRAFV600E and TERT promoter mutation/expression. Notably, in BRAFV600E mutated PTC, high EHF expression was associated with shorter disease-free survival. Cases harboring concurrent BRAFV600E, TERT promoter mutations, and high EHF expression exhibited the shortest disease-free survival. In cells harboring concurrent BRAFV600E and TERT promoter mutation, overexpression of EHF significantly increased TERT expression, whereas knockdown or pharmacological inhibition of BRAF significantly decreased both EHF and TERT expression. In addition, chromatin immunoprecipitation and quantitative PCR analysis suggested a potential binding of EHF in TERT promoter mutant cells but not in TERT promoter wild-type cells.
Conclusion
The ETS transcription factor EHF is associated with poor prognosis in PTC. This is potentially mediated by BRAF-induced upregulation of EHF, which in turn increases TERT expression in TERT promoter mutated cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 64, Sweden.
- The Cancer Hospital of the University of Chinese Academy of Sciences, (Zhejiang Cancer Hospital), Hangzhou 310022, China.
- Department of Medicine-Huddinge, Karolinska Institutet, Stockholm SE-141 83, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-171 76, Sweden.
- Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm SE-171 64, Sweden.
- Department of Medicine-Solna, Karolinska Institutet, Stockholm SE-171 76, Sweden.
ORCID-Profile: Yiyi Xu, Jan Zedenius, Catharina Larsson, Ninni Mu
Förderung
- Swedish Cancer Society
- Swedish Research Council
- Stockholm County Council
- Karolinska Institutet
- China Scholarship Council
Zitieren
APA
Xu, Y., Gao, J., Wang, N., Zedenius, J., Nilsson, I. L., Lui, W. O., Xu, D., Juhlin, C. C., Larsson, C., & Mu, N. (2025). BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 110(3), 693-705. https://doi.org/10.1210/clinem/dgae589
Vancouver
Xu Y, Gao J, Wang N, Zedenius J, Nilsson IL, Lui WO, et al. BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):693-705. doi:10.1210/clinem/dgae589
BibTeX
@article{Xu2025,
author = {Xu, Yiyi and Gao, Jiwei and Wang, Na and Zedenius, Jan and Nilsson, Inga-Lena and Lui, Weng-Onn and Xu, Dawei and Juhlin, C Christofer and Larsson, Catharina and Mu, Ninni},
title = {BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {3},
pages = {693--705},
doi = {10.1210/clinem/dgae589}
}
EUVIMED